Mallinckrodt Plc

Mallinckrodt Plc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)23.13
  • Today's Change-0.37 / -1.57%
  • Shares traded2.14m
  • 1 Year change-54.32%
  • Beta1.3043
Data delayed at least 15 minutes, as of Jan 16 2018 21:02 GMT.
More ▼

Events & Activity

  • MNK:NYQ price falls below 50-day moving average to 23.12 at 12:45 GMT
  • MNK:NYQ price moved over +1.00% to 23.13
  • MNK:NYQ price rises above 50-day moving average to 23.30 at 09:31 GMT
  • MNK:NYQ price falls below 15-day moving average to 23.06 at 13:11 GMT
  • MNK:NYQ price rises above 15-day moving average to 23.13 at 09:30 GMT

Key statistics

On Tuesday, Mallinckrodt Plc (MNK:NYQ) closed at 23.13, 21.74% above the 52 week low of 19.00 set on Nov 08, 2017.
52-week range
19.00Nov 08 201755.32Feb 22 2017
Markit short selling activity
Previous close23.50
Average volume2.40m
Shares outstanding95.00m
Free float93.86m
P/E (TTM)--
Market cap2.23bn USD
EPS (TTM)-0.0155
Data delayed at least 15 minutes, as of Jan 16 2018 21:02 GMT.
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.